News
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in ...
A self-administered, under-the-skin injection version of Saphnelo is effective for reducing disease severity in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback